Jazila Mantis
Infectious Disease · Jamaica, NYNPI 1710082847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Pfizer at 44.0% of the total.
Across 15 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$153
- E.r. Squibb & Sons, L.L.C.$43
- Johnson & Johnson$32
- GSK$25
- Shionogi Inc$23
- Aurinia Pharma U.S., Inc.$21
- plus $50 from 3 others
Across 49 payments — averaging $21,289 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1M
- Genentech, Inc.$4K
What the payments were for
- Food & beverage$347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $153 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Johnson & Johnson | 1 | $32 |
| GSK | 1 | $25 |
| Shionogi Inc | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Gilead | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
How this compares
$347 in reported general payments places this provider in the 55th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 26 | $78,660 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $64,269 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $54,122 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $47,888 |
| Entecavir | 12 | $832 |
| Rosuvastatin Calcium | 23 | $486 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $467 |
| Valsartan | 19 | $273 |
| Amlodipine Besylate | 26 | $184 |
| Oxcarbazepine | 12 | $107 |
| Metoprolol Succinate | 12 | $90 |
| Pantoprazole Sodium | 18 | $67 |
| Tamsulosin Hcl | 12 | $38 |
| Metformin Hcl | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $17 | $112,15740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 799 infectious disease providers in New York.
Other infectious disease in Jamaica
- Sonia PunjJamaica$50K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
- Stephen ThomasSyracuse$294K
- Glenn TurettFlushing$253K
- Genovefa PapanicolaouNew York$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.